NRX Pharmaceuticals (NRXP) Operating Income Growth (1y) (2019 - 2026)
NRX Pharmaceuticals (NRXP) Operating Income Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,462.92 Bn | 67,462.64 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,941.00 Bn | 1,940.94 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.07 Bn | 468.27 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 123.28 Bn | 116.03 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.12 Bn | 61.37 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.40 Bn | 62.40 Bn | - | - |
| 8 | Argenx Se | 56.45 Bn | 51.27 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 1,386.07% |
| 10 | NRX Pharmaceuticals | 120.25 Mn | 113.55 Mn | 437,000.00 | -23.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.26% |
| Dec 31, 2025 | -90.13% |
| Sep 30, 2025 | -33.16% |
| Jun 30, 2025 | 47.09% |
| Mar 31, 2025 | 35.86% |
| Dec 31, 2024 | 44.80% |
| Sep 30, 2024 | 47.97% |
| Jun 30, 2024 | 13.90% |
| Mar 31, 2024 | -55.91% |
| Dec 31, 2023 | 55.44% |
| Sep 30, 2023 | 36.46% |
| Jun 30, 2023 | 14.71% |
| Mar 31, 2023 | 75.50% |
| Dec 31, 2022 | 81.33% |
| Sep 30, 2022 | 54.52% |
| Jun 30, 2022 | 43.92% |
| Mar 31, 2022 | 38.66% |
| Dec 31, 2021 | -17.40% |
| Sep 30, 2021 | -290.33% |
| Jun 30, 2021 | -16,430.05% |